Pediatric precision oncology-Time for clinical prime time
- PMID: 35963231
- DOI: 10.1016/j.medj.2022.07.004
Pediatric precision oncology-Time for clinical prime time
Abstract
Recent prospective molecular tumor-profiling studies in pediatric cancer patients across a variety of different healthcare systems have highlighted both the feasibility and clinical utility of this approach. The current study by Church and colleagues in Nature Medicine1 has further substantiated this and laid the groundwork for a systematic collaborative approach to pediatric precision oncology in the US.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests S.M.P. receives grant support in the framework of an IMI-2 funded project from Eli-Lilly, Bayer, Roche, Pfizer, PharmaMar, Astra Zeneca, Amgen, Servier, Sanofi, and JnJ. S.M.P. holds a patent on a DNA-methylation-based method for classifying tumor species of the brain (EP3067432A1).
Comment on
-
Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer.Nat Med. 2022 Aug;28(8):1581-1589. doi: 10.1038/s41591-022-01856-6. Epub 2022 Jun 23. Nat Med. 2022. PMID: 35739269 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical